Instil Bio
TIL

$66.04

12.41%

Market Cap: $430M

About: Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Employees: 49

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

1.57% more ownership

Funds ownership: 65.43% [Q1] → 67.0% (+1.57%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

2% less capital invested

Capital invested by funds: $45.9M [Q1] → $44.8M (-$1.12M) [Q2]

3% less funds holding

Funds holding: 31 [Q1] → 30 (-1) [Q2]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

73%

downside

Avg. target

$98

48%

upside

High target

$180

173%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Mitchell Kapoor 48% 1-year accuracy 60 / 126 met price target	82%upside $120	Buy Reiterated	17 Sept 2024
HC Wainwright & Co. Mitchell Kapoor 48% 1-year accuracy 60 / 126 met price target	82%upside $120	Buy Maintained	16 Sept 2024
Baird Jack Allen 50% 1-year accuracy 5 / 10 met price target	173%upside $180	Outperform Reiterated	16 Sept 2024
Baird Jack Allen 50% 1-year accuracy 5 / 10 met price target	173%upside $180	Outperform Maintained	13 Sept 2024
HC Wainwright & Co. Mitchell Kapoor 48% 1-year accuracy 60 / 126 met price target	39%downside $40	Buy Maintained	12 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about TIL published over the past 30 days

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday.

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

Zacks Investment Research

Instil Bio Stock Skyrockets 641% in One Week: Here's Why

A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.

Instil Bio Stock Skyrockets 641% in One Week: Here's Why

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer (NSCLC) and in front-line triple-negative breast cancer (TNBC).

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

The Motley Fool

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?

Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 testing, but a similar candidate from Summit Therapeutics recently outperformed Keytruda.

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements

Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive advantages of IMM2510 would be the ability to bind to other VEGF ligands beyond that of VEGF-A only and to have enhanced ADCC killing. In-licensing deal with ImmuneOnco also brings on board next-generation anti-CTLA-4 antibody IMM27M, which also has enhanced ADCC killing.

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update.

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a definitive agreement pursuant to which Instil is in-licensing ex-China development and commercial rights to ImmueOnco's proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M.

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update.

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Zacks Investment Research

What Makes Instil Bio (TIL) a New Buy Stock

Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Instil Bio (TIL) a New Buy Stock

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update.

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

See News Rankings